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A fundamental premise associated with the use of atherapeutic agent is that for any given patient, the
clinical response can be predicted on the basis of the
selected drug product, dose, and dosing regimen. This
tenet provides the foundation for concepts of
prescribability and switchability.1 Prescribability refers
to an assumed relationship between a therapeutic out-
come and the rate and extent of drug exposure. A physi-
cian will prescribe a particular product in accordance
with assumptions pertaining to this relationship.
Generally, the process of drug movement from in-
take (e.g., oral delivery systems) to its site of action can
be schematically presented as follows (Figure 1).
As depicted in Figure 1, the relationship between
drug intake and a clinical response is highly complex,
potentially affected by a host of intrinsic and extrinsic
variables. Accordingly, deviations between drug re-
sponse within or between individuals may be ascribed
either to product bioavailability (i.e., the rate and extent
of drug absorption), drug pharmacokinetics (which in-
cludes themetabolism,distribution, andeliminationof
a compound), or the particular concentration-effect
relationship.
While product formulation can significantly affect
processes leading to drug absorption, once in the circu-
lation, the original formulation is generally considered
to no longer affect the ultimate drug response. In other
words, it is the concentration of the drug moiety, along
with its corresponding effect, that will ultimately de-
termine product safety and effectiveness. For this rea-
son, once a patient is titrated to a particular product
anddosing regimen,we assume that a comparable clin-
ical response will be achieved if the patient elects to
take a less expensive generic equivalent.
The purpose of this article is to discuss basic princi-
ples associated with the process of drug absorption.
Special attention will be given to the use of the
Biopharmaceutics Classification System (BCS) as a
predictive tool for identifying compounds whose ab-
sorption characteristics may be sensitive to intrinsic
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This article provides an overview of the patient-specific and
drug-specific variables that can affect drug absorption fol-
lowing oral product administration. The oral absorption of
any chemical entity reflects a complex spectrum of events.
Factors influencing product bioavailability include drug sol-
ubility, permeability, and the rate of in vivo dissolution. In
this regard, the Biopharmaceutics Classification System has
proven to be an important tool for predicting compounds
likely to be associated with bioavailability problems. It also
helps in identifying those factors that may alter the rate and
extent of drug absorption. Product bioavailability can also be
markedly influenced by patient attributes such as the integ-
rity of the gastrointestinal tract, physiological status, site of
drug absorption, membrane transporters, presystemic drug
metabolism (intrinsic variables), and extrinsic variables such
as the effect of food or concomitant medication. Through an
awareness of a drug’s physicochemical properties and the
physiological processes affecting drug absorption, the skilled
pharmaceutical scientist can develop formulations that will
maximize product availability. By appreciating the potential
impact of patient physiological status, phenotype, age, gen-
der, and lifestyle, dosing regimens can be tailored to better
meet the needs of the individual patient.
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(physiological) and extrinsic (e.g., food and formula-
tion) variables. Accordingly, this review focuses on
those factors that can affect drug dissolution, aqueous
solubility, membrane permeability, and presystemic
drug metabolism.
WHAT IS THE BCS?
One of the most significant prognostic tools created to
facilitate product development in recent years has been
the BCS.2 By knowing the solubility and permeability
characteristics of specific compounds, we improve our
ability to predict those variables (such as formulation,
food, dosing regimen, and disease) that will alter oral
drug absorption.
Currently, all pharmaceutical compounds are
grouped into one of the following categories:
Class I—high solubility, high permeability: generally very
well-absorbed compounds
Class II—low solubility, high permeability: exhibit disso-
lution rate-limited absorption
Class III—high solubility, low permeability: exhibit per-
meability rate-limited absorption
Class IV—low solubility, low permeability: very poor oral
bioavailability
Solubility is calculated on the basis of the largest
strength manufactured. It is defined as the minimum
solubility of drug across a pH range of 1 to 8 and at a
temperature of 37 ± 0.5°C. High-solubility drugs are
those with a ratio of dose to solubility volume that is
less than or equal to 250 ml. Permeability (Peff, ex-
pressed in units of 104 cm per second) is defined as the
effective human jejunal wall permeability of a drug.
High-permeability drugs are generally those with an
extent of absorption greater than or equal to 90% and
are not generally associated with any documented in-
stability in the gastrointestinal tract.
It is interesting to note that for certain compounds,
Peff is not necessarily constant. For example, nonlinear
changes in Peff were observed with increasing doses of
the surface-active molecule, fluvastatin. This nonlin-
ear increase in Peff was attributed to its effects on mem-
brane surface tension and to a possible decrease in
poly-glycoprotein (P-gp) activity associated with an in-
crease in intestinal membrane fluidity.3
The application of this system to nonhuman species
may require adjustment of these classification parame-
ters based on physiological differences in gastric vol-
ume and the pH of the gastrointestinal (GI) fluids. Ac-
cordingly, at this time, we cannot be certain that the
BCS classification of a compound remains constant
across all species. This question is currently being ex-
plored by the Food and Drug Administration’s (FDA’s)
Center for Veterinary Medicine.
By understanding the relationship between a drug’s
absorption, solubility, and dissolution characteristics,
it is possible to define situations when in vitro dissolu-
tion data can provide a surrogate for in vivo
bioequivalence assessments. The use of this surrogate
relies on the validity of three fundamental assump-
tions. First, it must be assumed that a comparison of
product in vitro dissolution performance accurately re-
flects relative differences in product in vivo dissolu-
tion behavior. Second, we must assume that if two
products present with equivalent in vivo dissolution
profiles under all luminal conditions, they will present
equivalent drug concentrations at absorptive mem-
brane surfaces. Third, for comparable dissolution pro-
files to ensure comparable in vivo absorption, the rate
and extent of drug presented to absorptive membrane
surfaces must determine the absorption characteristics
of that drug product.
Lobenberg and Amidon4 have summarized the rela-
tionships between dose, dissolution characteristics,
drug solubility, and drug absorption properties. These
relationships can be described as follows:
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Figure 1. Schematic diagram of the relationship between an oral
dose of a drug product and its ultimate effect.
1. Absorption number (An) = (Peff/R) • <Tsi>,
where R is the gut radius and <Tsi> the residence time
of the drug within the intestine.
2. Dissolution number (Dn) = (3D/r2) • (Cs/ρ) • <Tsi>,
where D is the diffusivity of the dissolved drug, ρ is the
density of the dissolved drug, Cs is the drug solubility,
and r is the initial radius of the drug particle.






where M is the dose of the drug and V0 is the volume of
fluid consumed with the dose.
The fractionofdrug absorbed is closely related to the
drug’s effective permeability across mucosal cells.4 If
the Peff of a drug is less than 2 • 10
–4 cm/s, then drug ab-
sorption will be incomplete, whereas complete absorp-
tion can be expected for substances whose Peff exceeds
this value. For poorly soluble drugs, critical variables
include the volume of the intestinal fluids, GI pH, and
GI transit time (where adequate time is needed to dis-
solve poorly soluble materials). For these lipophilic
compounds, food and bile salts may increase drug
solubility.
Class I compounds are highlypermeable and readily
go into solution (Dn > 1). In this case, the fraction ab-
sorbed (F) can be expressed as follows:
F = 1 – exp(–2An).
For these agents, as “An” increases, the fraction of
drug absorbed increases, with 90% absorption (highly
permeable compounds) occurring when An = 1.15. Re-
ferring back to the equation for An, we see that F can be
affected by a change in the compound’s membrane per-
meability, the gut radius of the host, or the intestinal
transit time. Based on these factors alone, it is evident
that differences in GI physiology due to factors such as
disease, age, or animal species can alter the value of An
and, therefore, the fraction of drug absorbed.
ForClass II drugs (highpermeability, lowsolubility),
Dn < 1. In these cases, the relationship between D0 and
Dn is critical for determining the fraction of drug ab-
sorbed, and the rate of drug dissolution tends to be the
rate-limiting step. Accordingly, anything that increases
the rate and extent of in vivo dissolution will also in-
crease the bioavailability of that compound.
SOLUBILITY
Aqueous solubility can be estimated by determining
the ability of a drug to partition from lipid to aqueous
environments. This partitioning behavior is often a
function of solvent pH due to the latter’s effects on drug
ionization. In general, ionized drugs tend to exhibit far
greater aqueous solubility than the un-ionized counter-
part. Consequently, the rate of solute dissolution in
aqueous media can be markedly affected by the pH of
that solvent.
To examine the effect of pH on drug ionization, one
can use a rearrangement of the Henderson-Hasselback
equation:5
Weak acid: % un-ionized = 100/(1 + antilog (pH-pKa)).
Weak base: % un-ionized = 100/(1 + antilog (pKa-pH)).
Weakly basic drugs tend to have a slower dissolution
rate at higher pH (when more drug exists in its un-
ionized form), whereas weakly acidic drugs dissolve
faster at higher pH (when more drug exists in its ion-
ized form). Examples of the relationship between the
percentage of drug in its un-ionized form as a function
of drug pKa and pH are found in Figures 2 and 3. For
this reason, by increasing the proportion of drug exist-
ing in its un-ionized state, meals that elevate gastric pH
can decrease the dissolution of a weak base. For exam-
ple, weak bases such as indinavir (with pKa of 3.7 and
5.9) are expected to precipitate when gastric pH is ele-
vatedduring ameal, resulting in a significant reduction
inAUCandCmax values in fedversus fastedhuman sub-
jects.6 Conversely, the same meal can increase the dis-
solution rate of a weak acid by increasing the propor-
tionof drug existing in its ionized state, therebymaking
it more water soluble.7
By definition, solubility is the extent to which mole-
cules from a solid are removed from its surface by a sol-
vent. While solubility may be expressed in many ways,
some generalizations can be made:8
Very soluble: Less than 1 part solvent needed to dissolve 1
part solute
Freely soluble: From 1 to 10 parts solvent needed to dis-
solve 1 part solute
Soluble: From 10 to 30 parts solvent needed to dissolve 1
part solute
Sparingly soluble: From 30 to 100 parts solvent needed to
dissolve 1 part solute
Slightly soluble: From 100 to 1000 parts solvent needed to
dissolve 1 part solute
Very slightly soluble: From 1000 to 10,000 parts solvent
needed to dissolve 1 part solute
Practically insoluble: More than 10,000 parts solvent
needed to dissolve 1 part solute
A compound’s aqueous solubility, as measured by its
propensity to distribute betweenoctanol andwater, is a
function of its ability to form hydrogen bonds with the
water molecule. Generally, aqueous solubility is di-
rectly proportional to the number of hydrogen bonds
that can be formed with water.9 As discussed later,
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while very high aqueous solubility is beneficial for
drug dissolution in aqueous media, these same com-
pounds often exhibit low permeability due to their
high polarity and poor lipophilicity.
Although lipid/water partitioning is often used to
describe drug solubility, there is some evidence that
solubility may better be described by the compound’s
dynamic energy properties.10 The solubility parameter
of any compound can be described in terms of the en-
ergy required to fragment a molecule into its constitu-
ent atoms (its cohesive energy). When described in
terms of the square root of its cohesive energy density
(energy of vaporization per unit volume), the solubility
parameter will lie on a scale from 10 (nonpolar) to 48
(water). For two materials to be miscible, their solubil-
ity parameters must be similar.
When comparing the percent absorbed versus log P
(octanol/water partition coefficient), the percent ab-
sorbed versus the solubility parameter, and the percent
absorbed versus the number of hydrogen bond accep-
tors, it was noted that a high level of negative correla-
tion was observed for the latter two relationships. Con-
versely, a large degree of scatter was observed in the re-
lationship between permeability and log P. It was also
noted that highly permeable compounds tend to have
solubility parameter values almost identical to that of
biological membranes (solubility parameter values of
20-26 MPa1/2). Accordingly, thermodynamic consider-
ations rather than physicochemical interactions10 may
serve as the best predictors of a compound’s membrane
permeability.
IN VIVO DRUG ABSORPTION
Efforts are currently under way to identify molecular
quantitative structure-bioavailability relationships
(QSBR) that predict drug bioavailability.11 Factors that
negatively influence bioavailability include the num-
ber of hydrogen bond donors, the presence of heavy at-
oms, and the inclusion of fragments such as tetrazole,
4-animopyridine, and benzoquinone. Factors that tend
to enhance drug bioavailability include the presence of
hydrogen acceptors, low molecular weight, and the
presence of fragments such as azide, salicylic acid, and
amides.
To understand reasons for these structure-
bioavailability relationships, it is important to recog-
nize the complex series of events that occur during the
process of drug absorption. Molecular movement
across lipid bilayers, such as those existing within bio-
logical membranes, is extremely complex due to the re-
gional differences inmembranepolarity, hydrophobicity,
and density. Generally, the bilayer can be divided into
four distinct regions.12 These include the following:
1. The first (outermost) region contains ahighproportion
of water molecules and may be the region responsible
for interactions with other membranes and proteins.
2. The second region has the highest molecular density
of all four regions (contains the polar headgroups),
contains little or no water, and exerts the greatest
barrier to solute diffusion (due to its density
characteristics).
3. The third region contains the highest density of
nonpolar tails. This region serves as the primary bar-
rier to membrane penetration and is primarily respon-
sible for the limitations in molecular size and shape
associated with membrane transport.
4. The fourth region is the most hydrophobic region of
the membrane, serving as a hydrophobic barrier in
membrane transport.
Owing to thismembranestructure, it is evident thatdrug
permeability is not a simply two-step process of
solubilization and diffusion but rather represents a
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Figure 2. Relationship between percentage of drug un-ionized, and















Figure 3. Relationship between percentage of drug un-ionized, and
pH and pKa of weak bases.
spectrum of complex molecular events. Accordingly,
intestinal permeability reflects a multifunctional inter-
action of factors such as molecular size (negatively cor-
related), lipophilicity (positively correlated), polar van
der Walls surface area (negatively correlated), and the
molecular flexibility (intramolecular hydrogen bond
formation).13
In addition to cellular membrane barriers to drug
diffusion, significant impedance is also effected by the
components of the gastric and intestinal mucous
layer.14 In examining the relative contribution of these
various components, it was noted that lipid constitu-
ents such as phosphatidyl choline, cholesterol, and
linoleic acid significantly retard the diffusion of small
lipophilic molecules such as propranolol and hydro-
cortisone. Conversely, small hydrophilic molecules
such as mannitol appear to freely diffuse through this
lipoid barrier. Mucous gel-forming components, such
as mucin and DNA, exert far less negative effects on the
diffusion of lipophilic molecules. However, they may
serve to block the diffusion of peptides and proteins.
Molecular flexibility and the corresponding ability
to undergo conformation changes can significantly af-
fect the polar surface area of a molecule. The polar sur-
face area and nonpolar surface area are powerful pre-
dictors of intestinal permeability, being respectively
inversely and directly related to membrane permeabil-
ity.15 However, anyparticular set of descriptorsmaynot
adequately predict membrane permeability across
nonhomologous compounds.9 Another important vari-
able is the strength of the hydrogen bonds formed be-
tween the molecules of water and solute.15 It is gener-
ally assumed that these bonds must be broken
(desolvation) before the solute can traverse the biologi-
cal membrane. Which of these factors play the domi-
nant role in determining drug permeability may vary
across homologous drug series.
Despite these complexities, certain generalizations
can be made with regard to drug absorption processes.
For example, the vast majority of orally administered
drugs are absorbedviapassive transcellular transport.15
This necessitates that the drug traverse through a
highly lipophilic membrane. Accordingly, diffusion
processes are governed by Fick’s laws of diffusion and
therefore influenced by the compound’s lipophilicity.
This ability to diffuse through lipids has been found to
be highly correlated with the ability of a drug to parti-
tion between water and an organic solvent such as
octanol. In fact,when expressed as logP0 (basedonpar-
titioning between n-octanol and water), the optimal
partition coefficient for adrug generally fallswithin the
range of 2 to 7.5 Nevertheless, exceptions do occur, and
while transcellular transport generally occurs when
the compound is un-ionized, recently, several ionized
molecules have been shown to be absorbed via
transcellular processes.16,17 This finding reinforces ear-
lier statements regarding the degree of scatter associ-
ated with the relationship between log P and drug
absorption.
In addition to passive mechanisms, active transport
is important to the absorption of several compounds.
Both active and passive transport mechanisms may oc-
cur simultaneously for the same molecule. Which of
these mechanisms has the dominant role tends to be
compound specific and may not be well predicted by
in vitro systems.15 Nevertheless, it must be remem-
bered that even active transport mechanisms require
that the drug penetrate the intestinal cells via the
transcellular route.
The rate of passive diffusion of any molecule,
whether it be absorbed via transport between mucosal
cells or through the mucosal membrane, can be de-
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where
dM/dt = the effective rate of passive drug
absorption (concentration/time).
Daq = the diffusion coefficient of the
compound in water.
λaq = the aqueous diffusion distance.
Jfluid = the fluid flow between epithelial cells.
α = the ratio of the water flow relative to the
solute flux, both under the influence of
the existing pressure gradient, and is
dependent on molecular size, volume,
charge, and hydration number. It may
also be influenced by the dynamic
width of the tight junction.
K = the partition coefficient describing the
relative tendency of the substance to
dissolve in the membrane phase (Cmembrane)
as compared to the surrounding aqueous
phase (Clumen).
Dm = the diffusion coefficient of the
compound within the membrane, which
is dependent on factors such as drug
lipophilicity, hydrogen bonding
capacity, polar surface area of the
molecular, molecular volume, and
shape.
Jmax = the maximal transport capacity of the
carrier-mediated process.
Km = the substrate specificity of the
membrane transporter (the Michaelis
constant).
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λ = the thickness of the rate-limiting
diffusion barrier.
Am and Ap = the available surface areas for
transcellular and paracellular
transport, respectively.
Thus, for passive diffusion, whether a drug is absorbed
via paracellular or transcellular mechanisms is deter-
mined by both physicochemical and physiological
factors.
Paracellular diffusion involves both diffusion and a
convective volume flow through water-filled
intercellular channels whose diameter is approxi-
mately 3 to 10 Å in humans.18 Accordingly, the size and
number of paracellular spaces influence the intestinal
absorption of most hydrophilic compounds. This, in
turn, is affected by the mucosal surface area and by cel-
lular density.19 Therefore, it is not surprising that the
bioavailability of small hydrophilic compounds tends
to be greater in species suchasdogs, inwhichbothpore
diameter and surface area tend to exceed that in hu-
mans.20 In humans, the small intestinal surface area for
paracellular absorption is approximately 0.01% of the
totalmembrane surface area. For this reason, unless the
molecule is extremely small (e.g., < 200 Da),
paracellular transportwill have aminor role indrug ab-
sorption.15
With permeability-limited absorption, we can ex-
pect that although the fraction of dose absorbed re-
mains unchanged, the absolute amount of drug ab-
sorbed will increase as dose increases (assuming linear
kinetics). Conversely, for solubility-limited com-
pounds, increasing the dose will have no effect on the
absolute amount of drug absorbed. Consequently, in
these cases, the fraction of dose absorbed will decrease
as dose is increased.21 Moreover, permeability is not
necessarily constant throughout the GI tract. While for
some compounds, drug absorption appears to be site
independent,22 for others, it is site dependent.23 When
drug absorption is site dependent, the availability of
dissolved drug at the absorption site can be the
rate-limiting factor in product bioavailability.
PRODUCT DISSOLUTION
Drug absorption depends on delivery of the drug parti-
cles to its site of absorption. The Noynes-Whitney










where dm/dt is the dissolution rate, expressed as the
change in the amount of drug dissolved (m) per unit
time (t); D is the diffusion coefficient; S is the surface
area; h is the thickness of the diffusion film adjacent to
the dissolving surface; Cs is the saturation solubility of
the drug molecule; Ct is the concentration of the dis-
solved solute; and V is the volume of the dissolution
medium.
Upon integration, this equation can be expressed as
follows:25
m = − −C
V
s ( exp( ))1 Kt
and
K = S • D/h.
The viscosity of the GI contents,23,26 as described by
the following equation, can affect D, the diffusion
coefficient:
D = (KbT)/(6πR0η),
where D is the diffusivity of a compound, Kb is the
Bolzmann constant, T is the temperature, R0 is the sol-
ute radius, and η is the viscosity of the diffusion
medium.
As seen in the latter equation, increasing the surface
area of a particle (S) can enhance its dissolution rate. S
can be increased by micronization, a process some-
times applied to poorly water-soluble compounds.24
Also to be considered are particle size and density,
which both inversely affect the dissolution rate.27 Parti-
cle shape is also important in determining the dissolu-
tion behavior of a drug, and for many crystalline forms
(particularly shapes of needles and platelets), shape
and consequently dissolution behavior may change
markedly as the particle dissolves.28,29
Particle properties can also affect the rate of GI tran-
sit, the latter being highly dependent on such proper-
ties as size, shape, and density. For example, in swine,
about 30% to 40% of ingested food materials pass into
theduodenumwithin 15minutes in an adult pig.How-
ever, large particles (10 mm in diameter) are retained
within the stomach of swine for several days, with resi-
dence time increasing with particle density and
length.30
A problem with the Noynes-Whitney equation is
that there is an inherent assumption that S remains
constant over time. Unfortunately, this assumption is
incorrect, and the S of powders and immediate-release
preparations tends to decrease as dissolution pro-
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ceeds.25 In vivo, many of these parameters are also in-
fluenced by the conditions of the GI tract, which will
vary over time.31 For this reason, these equations,while
providing insights into the parameters that can affect
drug dissolution, should not be blindly applied to pre-
dict in vivo dissolution rate.
It should be noted that because the Noynes-Whitney
equations are unable to adequately model either
S-shaped data or data with a steep initial slope, the
more general Weibull distribution has been used to de-
scribe dissolution profiles.25 The Weibull distribution
can be described as follows:
M = 1 – exp(–αtβ),
where M is the accumulated fraction of material in so-
lution at time t, α is a scale parameter, and β is a shape
parameter, where β = 1 indicates an exponential rela-
tionship, β > 1 indicates an S-shaped relationship, and
β < 1 indicates an exponential relationship with a steep
slope.
The rate of product dissolution may or may not in-
fluence the resulting plasma concentration-time pro-
file. For example, Class I compounds (highly soluble,
highly permeable) may exhibit marked difference in
the in vitro dissolution profiles without any resulting
differences detected in product bioavailability.32-34 In
these instances, gastric emptying is slower than prod-
uct dissolution. Accordingly, it is the rate of gastric
emptying rather than product performance that is the
rate-limiting step in determining the bioavailability
characteristics of that formulation. Similarly, highly
soluble, poorly permeable compounds (Class III) dis-
solve rapidly. However, in these cases, it is not the rate
of drug dissolution that is usually rate limiting but
rather the rate of permeation across biological mem-
branes. Therefore, we can again assume that so long as
dissolution is faster than the rate of gastric emptying,
product dissolution will not determine product
bioavailability. In the case of Class III compounds, so
long as absorption occurs via linear processes, the ab-
solute amount of drug absorbed may be increased by
increasing the dose.21
On the other hand, for high-permeability, low-
solubility compounds (Class II), the rate and extent of
product dissolution will have a significant role in de-
fining the resulting blood concentration-time profile.27
This may be attributable to problems associated with
either particle size (termed dissolution-limited absorp-
tion) or drug solubility (termed solubility-limited ab-
sorption). In the case of solubility-limited absorption,
particle size exerts minimal effect on the fraction of
drug absorbed. In this situation, fraction of drug ab-
sorbed can only be improved by enhancing drug
solubility (e.g., via the inclusion of surfactants in the
product formulation). Conversely, particle size exerts
its greatest effect when solubility is not a problem. In
these cases, a significant improvement in the fractionof
drug absorbed can be achieved by increasing surface
area (i.e., decreasing particle size).
The FDA’s Center for Drug Evaluation and Research
(CDER) has written a guidance that provides for the
waiver of in vivo bioequivalence study requirements
for high-solubility/high-permeability drug products
based on in vitro dissolution data. The scientific and
regulatory considerations that must be applied to these
procedures are described in the CDER guidance titled
Waiver of In Vivo Bioavailability and Bioequivalence
Studies for Immediate-Release Solid Oral Dosage
Forms Based on a Biopharmaceutics Classification
System (August 2000). For Class I compounds, the
bioequivalence of generic or revised versions of mar-
keted drug products can be confirmed if the sponsor can
demonstrate that gastric emptying is the rate-limiting
step in product absorption.
To be granted a waiver of in vivo bioequivalence
study requirements, the CDER recommends that in vi-
tro dissolution tests be conducted under the following
conditions:
• The test apparatus is USP Apparatus I at 100 rpm or
Apparatus II at 50 rpm. Testing is conducted in 900 ml
of each of the following dissolution media: (1) 0.1 N
HCl or Simulated Gastric Fluid USP without enzymes,
(2) a pH 4.5 buffer, and (3) a pH 6.8 buffer or Simulated
Intestinal Fluid USP without enzymes.
• For each formulation, a minimum of 12 dosage units is
evaluated to support a biowaiver request. Samples
should be collected at time intervals adequate for char-
acterizing the dissolution profile of the drug product.
When comparing the test and reference formulations,
the respective dissolution profiles should be compared






























where Rt is the percent dissolved of the reference prod-
uct, Tt is thepercent dissolvedof the test product, andn
is the number of units tested.
• Two dissolution profiles are considered similar when
the f2 value is ≥ 50. To allow the use of mean data, the
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coefficient of variation should not exceed 20% at the
earlier time points (e.g., 10 minutes) or 10% at all other
time points. If, under all dissolution conditions, both
the test and referenceproducts dissolve at a rate of 85%
or more within 30 minutes, profile comparisons are not
necessary.
The BCS and in vivo/in vitro correlation concepts
(IVIVC) have also been incorporated into several CDER
guidances pertaining to scale-up and postapproval
changes for immediate-release and sustained-release
dosage forms. As with products that contain Class I
compounds, in vivo bioequivalence determinations for
certain types of postapproval changes may be gener-
ated on the basis of in vitro dissolution data. For more
information in this regard, refer to theCDERWebsite.35
The absorption of controlled-release dosage forms
is, by definition, dissolution-rate limited. Since drug
permeability characteristics must be sufficiently high
to ensure the presence of sink conditions within the GI
tract, the appropriate candidates for these products are
Class I or II compounds.36 Moreover, to develop an
IVIVC for these products, test procedures must account
for the changing environments towhich theoral dosage
form will be exposed as it traverses down the GI tract.
These include the following:
• the impact of changes in fluid volume, surfactants, and
motility patterns on product dissolution and drug
solubility;
• regional differences in intestinal permeability and sur-
face area;
• regional differences in intestinal metabolism and
secretions.
PRESYSTEMIC DRUG METABOLISM
Oral bioavailability (F) can be described as follows:37
F = fabs • (1 – fg) • (1 – fh),
where fabs is the fraction of the dose absorbed from the
GI lumen, fg is the fraction of drug metabolized by the
gut wall, and fh is the fraction of drug metabolized by
the liver.
An excellent example of the importance of first-pass
metabolism is exemplified by the impact that
interspecies differences in drug metabolism have on
product bioavailability. For example, the observed
interspecies differences in the oral bioavailability of
indinavir (72% in dogs, 24% in rats, and 19% in mon-
keys) is attributable to species differences in hepatic
first-pass extraction (approximately 68% in rats, 65%
inmonkeys, and17%indogs).38 In human subjects, the
oral bioavailability of indinavir is approximately
60%.39
Lin et al37,38 provide an excellent discussion of fac-
tors that can affect the clearance and therefore overall
bioavailability of compounds. He describes hepatic
clearance (CLH) as follows:
CLH = Qh • E, and E = [(fb • CLint)/(Qh + fb • CLint)],
where Qh is hepatic blood flow, E is the hepatic enzyme
extraction ratio, fb is theunbound fractionof drug in the
blood, and CLint is the intrinsic clearance (a measure of
Vmax/KM).
When Qh >> fb • CLint, then CLH = Qh • [(fb • CLint)/(Qh
+ fb • CLint)], which tends toward
fb • CLint • Qh/Qh
= fb • CLint • 1
= fb • Clint.
Conversely, when Qh << fb • CLint, then CLH ~ Qh.
For high E compounds, CLH is said to be blood flow
limited (i.e.,Qh << fb •CLint). In otherwords,CLH will be
affected by anything that can alter Qh (or Qh-splancnic for
oral first-pass effects). In these cases, factors altering in-
trinsic clearance (CLint), such as drug-drug interactions,
should have minimal impact on CLH. Alternatively, for
low E drugs, CLH ~ fb • CLint. In this situation, any factor
that alters fb, Vmax, or KM can markedly affect CLH.
An example of these interrelationships is seen with
the interaction between indinavir (oral or intravenous
administration) and ketaconazole (oral administra-
tion).38 In rats, indinavir is a high-clearancedrugwhose
CLint (80-90 ml/min/kg) exceeds the Qh (60-70
ml/min/kg). Ketoconazole is a low-clearance drug.
Ketoconazole competitively inhibits the metabolism of
indinavir, and indinavir inhibits the metabolism of
ketaconazole. As expected, since CLint exceeds sys-
temic blood flow to the liver, ketoconazole has practi-
cally no effect on the AUC of intravenously adminis-
tered indinavir. However, when indinavir is
administered orally, drug coadministration results in
an increase in indinavir bioavailability from about
20% in the control group to 89% in the ketoconazole-
treated group. Clearly, the difference is attributable to
first-pass metabolism. However, the question is
whether differences between intravenous versus oral
results were attributable to the effect of ketoconazole
on the liver, small intestine, or both.
When indinavir is orally administered, the entire
dose passes through the liver. Accordingly, we expect
greater hepaticdrug losswhen thedrug is administered
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orally versus parenterally. Alternatively, we must also
consider the possibility that the increase in indinavir
oral bioavailability was attributable to the effect of
ketaconazole on intestinal first-pass drug metabo-
lism.40 That both mechanisms were likely to have been
operative was strongly suggested by the results ob-
tained when indinavir (intravenous vs. oral doses) was
coadministered with dexamethasone.41 In the latter
study, dexamethasone induced the activity of bothCYP
3A and P-gp, and the authors demonstrated that while
both liver and gut metabolism were potentiated, dexa-
methasone had a substantially greater impact on the
hepatic metabolism. At least in part, these studies un-
derscore the importance of considering the route of ad-
ministration when considering the impact of potential
drug-drug interactions.
Lin et al37 emphasize that the greater changes in
bioavailability seen after oral versus parenteral admin-
istration should not automatically be attributed to a
greater degree of enzyme induction/inhibition in the
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where fabs is the fraction of drug absorbed; FH and FG are
the fraction of drug not metabolized by the liver or gut,
respectively; fB is the unbound fraction of drug in
plasma; andCLint, h andCLint, g are the intrinsic clearance
of the liver and gut, respectively.
Based on these equations, it can be seen that in-
creases in CLint, h and CLint, g will be offset by the multi-
pliers FH and FG when the drug is administered by a
nonoral route (e.g., intravenous injection). In other
words, as hepatic or intestinal clearance increases (e.g.,
due to the coadministration of an enzyme inhibitor),
the fraction of drug not metabolized will increase.
Therefore, the values FH •CLint, h andFH •FG •CLint, g are
diminished, minimizing the resulting changes in
AUCIV. Conversely, after oral administration, an in-
crease in hepatic clearance will be amplified by divid-
ing CLint, h by FG. In addition, intestinal clearance is not
counteracted by the concomitant changes in the frac-
tion of unmetabolized drug. For this reason, changes in
AUCPO will generally exceed changes in AUCIV associ-
ated with the coadministration of an enzyme inducer
or inhibitor. Using simulations, Lin et al37 demon-
strated that both enzyme induction and inhibition will
have a less profound effect on AUCIV as compared with
AUCPO, regardless of whether the compound in ques-
tion is a high- or low-clearance drug.
The latter study points to the importance of consid-
ering the small intestine as a potential site of drug me-
tabolism. Substantial drug loss can occur via intestinal
efflux mechanisms, gut wall metabolism (both Phase I
and Phase II), and degradation within the gut lu-
men.37,42,43 The cytochromeP450 systemconstitutes the
principle enzymes involved in the biotransformation
of drugs and other substances.37 Approximately 70% of
the human liver P450 is accounted for by CYP1A2,
2A6, 2B6, 2C, 2D6, 2E1, and 3A isoforms.37 While the
total amount of P-450 in the human intestine is much
less than that in the liver (20 pmol/mg microsomal pro-
tein vs. 300 pmol/mg microsomal protein, respec-
tively), the intestinal enzymes are strategically situated
to maximize their exposure to intestinal contents. P450
concentrations tend to be greatest in the villus tips of
the upper and middle third of the intestine.44
Examples of drugs subject to gutwallmetabolism in-
clude midazolam,45 amoxicillin,46 and cyclosporin.47
Interestingly, several major Phase I metabolizing en-
zymes co-reside at the villus tips, providing a highly ef-
ficient mechanism for drug degradation.48 Of particular
importance is the synergistic function of P-gp and
cytochrome P450 3A4, which together are responsible
for the active extrusion and subsequent metabolism of
a wide variety of compounds.49 The latter is discussed
in more detail in the section of this review that focuses
on membrane transporter systems.
Compounds may also be extensively metabolized
in the gut lumen by digestive enzymes or by activity of
the gut microflora. An excellent example of the poten-
tial negative impact of microbial metabolism is the
species-by-route differences in blood concentrations
achieved when chloramphenicol is administered to
goats, pigs, dogs, cats, and horses. Despite high levels
achieved in the goat after intramuscular administra-
tion, the oral bioavailability of this compound was
minimal due to microbial degradation in the gut. Simi-
lar problems did not occur with the other animal spe-
cies.50 Conversely, the presence of gut microflora may
enhance drug bioavailability by promoting biliary re-
cycling of compounds such as ouabain, digoxin, and
steroid hormones (e.g., Aldercreutz et al51). In these
cases, the bacteria remove the polar moiety from the
derivatizedconjugates, rendering themavailable for in-
testinal absorption.42
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When evaluating the impact of drug metabolism on
product bioavailability, patient phenotype should be
considered (see Lu et al,52 Mancinelli et al53). Of equal
importance may be the potential impact of certain nu-
trients, hormones, and inflammatory processes on the
activity of these enzymes,54 as well as that of concomi-
tantmedications. In this regard,Dr. DavidA. Flockhart,
MD, PhD, in the Division of Clinical Pharmacology at
Georgetown University, has developed a free database
summarizing substances that act as substrates, induc-
ers, and inhibitors of the P450 enzymes. The database
includes Medline links to pertinent references for each
of these substrates.55
FORMULATION EFFECTS
By understanding the relationship between Dn, D0, and
An, we can assess whether a product’s bioavailability
will be solubility, permeability, or dissolution rate lim-
ited. Amidon et al2 list several factors that can affect in
vivo drug absorption characteristics. These include the
following:
• pH dependent solubility of the active ingredient,
• drugs that form insoluble complexes with the GI
contents,
• instability in the GI tract,
• physicochemical interaction of drug particles. For ex-
ample, to enhance the rate of drug dissolution of Class
II compounds, the drug particles may be micronized.
While this generally increases particle surface area
(and therefore drug dissolution), micronized particles
may also have a greater tendency to form aggregates,
thereby decreasing drug dissolution.
Surface area (S from the Noynes-Whitney equation)
can be enhanced via the use of wetting agents that
lower the surface tension of the dissolution medium.
Examples include dispersing agents such as polyethyl-
ene glycol and polyvinyl pyrrolidone or complexing
agents such as cyclodextrins.24,56 However, surface-
active agents that increase drug water solubility are not
generally used in product formulations because the
amount of surfactant needed to enhance in vivo prod-
uct dissolution may compromise product safety.24 In
the case of some very poorly water-soluble drugs, the
inclusion of insoluble carriers may provide a mecha-
nism for maintaining the concentration gradient (Cs-Ct)
at its maximum.24
For drugs that exhibit high solubility, low intestinal
permeability, it is intestinal permeability that is the
rate-limiting step in drug absorption.57 In the BCS sys-
tem, these are considered Class III compounds. A con-
sequence of permeability-limited absorption is that the
rate of dissolution is generally far less important than
the rate of GI transit. Consequently, formulations of
Class III compounds may exhibit markedly different
rates of dissolution without affecting any difference in
the blood concentration-time profile.58 However,
Class III compounds may be extremely sensitive to the
potential excipient effects on GI transit time and
permeability.
Some excipients are known to exert direct physio-
logical affects. For example, owing to its osmotic activ-
ity, certain sugar alcohols (e.g., mannitol) decrease GI
transit time, resulting in more rapid product transit
through the intestine.59 Another compound known to
alter GI transit time is sodium acid pyrophosphate.60
Consequently, if the drug is slow to dissolve, the inclu-
sion of these agents could significantly reduce product
bioavailability. Obviously, these excipient effects
would go undetected by tradition in vitro dissolution
methods. Other examples of potential in vivo excipient
effects that could goundetectedduring invitrodissolu-
tion testing include the affect of surfactants on mem-
brane permeability (e.g., Del Estal et al61) and the inhi-
bition of efflux pumps.62,63 Accordingly, one cannot
necessarily view excipients as benign inactive ingredi-
ents but rather as potentially powerful components
that can affect all aspects of drug bioavailability.
For excellent reviews regarding theuse of excipients
in product formulation and their potential effects on
drug bioavailability, refer to Monkhouse and Lach,64
Kalinkova,65 and Pifferi et al.66
VARIABLES THAT CAN AFFECT
PRODUCT BIOAVAILABILITY
Food Effects
The effect of food on drug oral bioavailability is ex-
tremely complex, and the underlying reason for food
effects appears to differ with different agents. For ex-
ample, in some cases, it appears that caloric content is
an important variable contributing to the magnitude of
the food effect. In other cases, caloric content appears
to have minimal influence on drug bioavailability.23.
Whendrugabsorption is facilitatedby surfactants, food
may enhance product bioavailability. In other cases, it
can have negative effects on both the rate and extent of
absorption as the drug binds to food constituents.23
Depending on thephysicochemical properties of the
compound, food-induced changes in gastric emptying,
along with an increase in gastric pH, may increase, de-
crease, orhavenoeffect ondrugavailability.7 For exam-
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ple, certain antibacterial products are acid labile, and
increased drug degradation due to prolonged gastric
residence may result if the dose is coadministered with
food. In other cases, meal-induced alterations in gastric
pH may affect drug absorption. Poorly soluble weak
bases may precipitate in the presence of food-induced
gastric pH elevations. Conversely, the degree of ioniza-
tion may increase when a weak acid is exposed to a
meal-induced increase in gastric pH, thereby enhanc-
ing its solubility and bioavailability.7 Alternatively,
some weak bases exhibit decreased bioavailability in
the presence of a high-fat meal due to the formulation
of a drug-bile acid complex.67
These factors are discussed below, with particular
considerationgiven todrug solubility andpermeability
characteristics.
Effect of Meals on GI Transit Time
The rate atwhich the fluid empties is highlydependent
on the phase of the electrical cycle observed in mam-
malian GI systems. Cyclic motor activity has been ob-
served under fasting conditions in both humans and
dogs.68-71 These interdigestive migrating myoelectric
complexes (IMMC) occur on the order of once every 90
to 120 minutes and are characterized by three phases:
• Phase I: the quiescent period
• Phase II: intermittent and irregular contractions
• Phase III: brief period of intense contractions. This
phase is responsible for moving both liquid and solid
materials down the GI tract.
By increasing fluid volume, the gastric emptying rate
increases,72 regardless of the phase of IMMC phases.68
The effect that smaller volumes exert on the rate of gas-
tric emptying ismore greatly influencedby thephaseof
stomach activity than is seen with larger fluid vol-
umes.68 This relationship can affect the variability ob-
served in the bioavailability of a dosage form. Accord-
ingly, fluid volume may be particularly important for
drug classes where dissolution is rapid and the avail-
ability of dissolveddrug to the intestinal tract is limited
by the rate of gastric emptying (BCS Class I and III
compounds).
The Effect of Nutrients on Drug
Uptake: Uncertainties Surrounding
the Importance of Solvent Drag
Transmucosal fluid flow appears to increase the mem-
brane permeability of both hydrophilic and lipophilic
compounds.18 This phenomenon is known as solvent
drag. For certain small hydrophilic molecules, it is
likely that a meal-induced increase in water absorption
will effect an increase in intestinal permeability. These
effects appear to be attributable to the impact of nutri-
ents on solvent drag and to water-transport changes in
drug access to paracellular pathways.52 However, in
other situations, the physiological relevance of solvent
drag has been questioned.18
Small hydrophilic molecules are generally absorbed
within 4 hours after dosing in man, after which absorp-
tion ceases, most probably due to drug entry into the
large bowel.18 Based on studies conducted in vitro, in
situ, and in vivo (perfusion models), it is observed that
the absorption of nutrients significantly increases the
membranepermeability of hydrophilicmolecules (mo-
lecular weight [MW] 60-5500). While solvent drag has
been repeatedly demonstrated in model systems, its
applicability to human drug absorption and its utility
as a mechanism for enhancing the bioavailability of
low-permeability compounds in humans has been
questioned.18 Moreover, while solvent drag may facili-
tate the absorption of small hydrophilic molecules, en-
hanced fluid absorption may impede the absorption of
Class II molecules. In this case, drug solubility is a
rate-limiting variable. Therefore, an increase in water
absorption may decrease GI fluid volume and conse-
quently lead to drug precipitation within the gut
lumen.
More recently, using two in vitro preparations,
Caco-2 cell monolayers and rat ileal mucosa, it was
concluded that the stimulation of epithelial water ab-
sorption is inadequate to enhance paracellular intesti-
nal drug absorption.73 However, other work has sug-
gested that the intestine is a heteroporous membrane
consisting of several sizes of pores whose diameters are
dependent on the specific villus region.74 It was pro-
posed that the absorbing apical part of the villus con-
tains small pores (radius<6Å),while those in the basal
part of the villus are somewhat larger (10-14 Å), and
those in the crypts are larger still (50-60 Å). In this rat
study, active glucose transport was found to increase
the absorption of mannitol (~3.5 Å) while not affecting
absorption of the larger molecules, suggesting that sol-
vent drag may occur in a region-specific manner. It was
noted, however, that the identical protocol did not pro-
duce comparable findings in the cat,75 which could in-
dicate the possibility of species-specific differences in
pore size distribution and the importance of solvent
drag.
Meal Effects on Drug Diffusivity
The effect of meal viscosity on drug absorption will de-
pend on whether or not there exists site-specific ab-
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sorption, particularly if absorption is limited to the up-
per portions of the small intestine.23,76 If the drug
exhibits site-specific absorption, then meal-induced
decrease indiffusivity (D)may impededrug absorption
as the drug moves past the absorption site. However,
the effect of initial meal viscosity on D tends to dimin-
ish as the meal moves down the small intestine, an ef-
fect attributed to digestion and the release of GI fluids.
Therefore, if the drug is absorbed throughout the small
intestine, then meal viscosity should have little effect
on the extent of drug absorption.
When present, altered drug absorption associated
withmeal viscosity appears to be attributableprimarily
to altered fluid flow dynamics rather than to altered GI
motility.76,77 However, only modest changes in gastric
emptying rate are observed when viscosity increases
above 15,000 cp. Accordingly, viscosity-induced de-
lays in gastric emptying are primarily seen when com-
paring changes that occur within the lower range of po-
tential viscosity values.76 For this reason, viscosity
effects on drug bioavailability are generally considered
to be primarily a consequence of the effect of viscosity
on D.6 This relationship can be explained by the
Noynes-Whitney equation, where the drug dissolution
rate (dm/dt) is directly proportional the diffusion coef-
ficient (D).
The Effect of Nutrients on
First-Pass Drug Metabolism
Intestinal P450s tend to respondmore rapidly to induc-
ers as compared to hepatic P450 enzymes. It has been
postulated that this discrepancy is related to a greater
availability of these inducer substances to the intesti-
nal mucosa. Consistent with this postulation is the ob-
servation that while dietary restriction of iron causes a
marked and rapid decrease in intestinal P450 concen-
trations and oxidative enzyme activities, these activi-
ties are restored within 24 hours when iron is adminis-
tered via oral but not parenteral dosing.44
There are numerous examples of enzyme modula-
tors in the foods we consume.44,78 These include the
following:
• Charcoal-broiled and smoked foods: These polycyclic
aromatic hydrocarbons are potent inducers of CYP1A1
and CYP1A2. Examples of drugs whose bioavailability
may be decreased because of these effects include
pheacetin and theophylline.
• Grapefruit juice: An undefined compound within
grapefruit juice is recognized to inhibit both PGP (a
multidrug resistanceprotein) andCCYP3A.As a result,
there is enhanced bioavailability of compounds such
as estradiol, felodipine, and cyclosporin.
• Cruciferous vegetables: These can induce several en-
zymes that include Phase II enzymes such as
glutathione-s-transferase and quinone oxidoreductase
and Phase I enzymes such as the CYP1A subfamily.
• Watercress: This is an inhibitor of CYP2E1.
• Red and black pepper: These contain capsacin, which
inhibits CYP1a, CYP2B, and CYP2E1.
• Black pepper: This contains piperine, which inhibits
CYP1A and glucuronidation.
• Sodium chloride: High levels may increase CYP3A
activity.
For drugs exhibiting a large first-pass effect, concomi-
tant intake with food may increase drug availability. A
classical example of this is propranolol;79 as a result
of, in part, its saturable first-pass metabolism, a food-
induced increase in hepatic drug delivery can lead to
reduced presystemic metabolism. Another critical
variable is the volume of fluid taken with the dose,
whereby increasing the volume of fluid intake from 25
ml to 250 ml significantly increases the rate and extent
of aspirin bioavailability.72,80 This relationship appears
to be attributable to the decrease in first-pass metabo-
lism associated with a fluid volume-induced decrease
in GI transit time.
There appears to be little correlation between the ex-
pression of a particular metabolizing enzyme in the in-
testine versus that in the liver. This results in marked
interindividual variability in the relative contributions
of the intestine versus liver to first-pass drug loss, a
point that needs to be considered by physicians when
prescribingdose amount anduse conditions topatients
across a range of phenotypic populations. Moreover, as
seen in studies previously referenced in this review,
the oral administration of an inducer or inhibitor may
have a greater impact on GI enzymes as compared with
the more distal hepatic enzymes.78 Therefore, in terms
of formulation considerations, this difference in rela-
tive activities may alter the impact, including enzyme
modulators, in product formulations.
For further information in this regard, an extensive
list of metabolic pathways and associated information
can be obtained through the World Wide Web.81
APPLYING BCS CONCEPTS
TO PREDICT THE IMPACT OF
PHYSIOLOGICAL STATE
AND FOOD ON PRODUCT
BIOAVAILABILITY
There arenumerous exampleswhere anapriori knowl-
edge of a compound’s physicochemical properties and
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BCS classification can help predict its bioavailability
under a given set of conditions. For example, weak
bases with poor aqueous solubility (such as
dipyridamole and ketaconazole) are often associated
with absorption problems in achlorhydric individu-
als.82,83 Similarly, we would expect that the
bioavailability of these compounds will be compro-
mised in the presence of food.
GI transit time can also be altered by a number of fac-
tors, including age, food, drug excipients, disease, and
even some over-the-counter medications.7 In this re-
gard, the BCS can be used to predict those compounds
whose bioavailability may be particularly sensitive to
changes in GI transit. Insight in this regard can be ob-
tained from the results of studies suggesting that ani-
mal species with rapid GI transit (e.g., dogs) may be
more sensitive to changes in the invivodissolution rate
as compared to species with a longer transit time such
as swine.84 Thus, we can predict that Class II com-
pounds (high permeability, low solubility) that tend to
have dissolution rate-limited absorption may be partic-
ularly sensitive to factors that influence GI transit time.
These factors alonemayexaggeratedifferences in the in
vivo bioavailability, rendering products inequivalent
under certain sets of conditions (affecting switchability).
Conversely, we would not expect to see marked
changes in product-relative bioavailability for Class III
compounds (low permeability, high solubility) in re-
sponse to decreased GI transit time. In these cases, it is
drug absorption, not dissolution, that is the rate-limiting
step (i.e., switchability of two products will remain rel-
atively unaffected). However, we are likely to see that a
decrease in GI transit time will decrease drug
bioavailability, therebyaffectingproductprescribability.
Individuals from areas of poor hygiene and sanitation
appear to have significantly lower absorptive capaci-
ties, a finding that appears to be correlated with
changes in intestinal morphology connected with
subclinical infections.85 Therefore, these individuals
may potentially exhibit poor bioavailability of many
Class III compounds.
The conditions of the GI tract, including the number
of villi, microvilli, motility, probability of forward mo-
lecular movements, prandial state, and fluid volume,
can greatly affect drug absorption.86 Given that these
conditions change markedly across the length of the GI
tract, the gut must be viewed as a complex heteroge-
neous system. Traditionally, drug absorption processes
are modeled in accordance with the assumption of
time-invariant processes (rate constants). While this
may be correct for rapidly dissolving drugs (e.g., Class I
and III compounds), it is unlikely to be the case for
drugs that are absorbed throughout the GI tract or that
dissolve throughout the length of the small intestine. In
the latter situations, dissolution and uptake processes
are subjected to highly variable conditions, and the use
of well-stirred models is inappropriate.87
The assumption of time invariance is traditionally
employedbypharmacokineticists.While time-invariant
absorption may adequately describe Class I com-
pounds (as well as some Class II and III compounds), it
cannot adequately describe drugs with very low solu-
bility and/or permeability. Therefore, the use of
time-variant models may be more appropriate for de-
scribing the absorptionof certainClass II, III, or IV com-
pounds.84 It may also be useful to describe the effect of
food on drug absorption, particularly since the impact
of food on GI environment and viscosity decreases as
the meal traverses the small intestine.
Fleisher et al7 provide an excellent review of the
variables that can affect product bioavailability. In
brief, some of the factors that can potentially affect oral
drug bioavailability include the following:
1. Anything that can alter GI pH, including meals, drugs,
age, and disease
2. Complexation and chelation between drug and metal
ions (e.g., decrease in fluoroquinolone bioavailability
due to complexation with metal ions)
3. Drug adsorption onto meal components such as
pectins and fiber (e.g., decrease in penicillin V
bioavailability due to binding to dietary fiber)
4. Acid instability (e.g., decrease inoral bioavailability of
erythromycin), requiring products to be formulated ei-
ther with enteric coatings or with an antacid to mini-
mize drug instability (e.g., didanosine, an acid-labile
reverse transcriptase inhibitor)
5. Enzymatic hydrolysis of orally administered peptides
and proteins, necessitating novel formulation (e.g.,
prodrugs, or encapsulated formulations)
6. Meal-induced increase in viscosity in the duodenum
(affects primarily those drugs absorbed in the upper
small intestine), thereby impeding drug absorption
7. Altered gastric emptying time due to stomach volume,
calories, osmolarity, viscosity, and temperature. Solid
meals tend to empty more slowly than liquid meals,
although high-calorie liquid meals can delay gastric
emptying. Undissolved particles of a diameter less
than 1 to 12 mm will tend to empty with the fluid.
8. Product excipients that directly affect GI transit time
9. Increase in splanchnic blood flow: This may increase
the oral absorption of certain low first-pass effect
drugs or those high first-pass effect compounds that
are absorbed in the upper part of the small intestine
and that exhibit saturable first-pass metabolism. Con-
versely, it may decrease the bioavailability of high
first-pass effect compounds that do not exhibit satura-
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tion kinetics or that are absorbed throughout the small
intestine.
10. Food effects: These effects are considered relative to a
drug’s pKa and its BCS classification:
• Class I compounds are, by definition, highly solu-
ble across a wide range of pH values. Therefore,
food is not expected to alter the extent of product
absorption. However, the delay in gastric emptying
may affect peak drug concentrations or the time to
peak drug concentrations.
• Class II compounds exhibit low solubility and high
permeability. Accordingly, anything that can en-
hance its in vivo dissolution will also increase
product absorption. Due to the low solubility of
Class II compounds, high-fat meals (which cause
increased GI secretions and biliary solubilization)
will generally enhance drug dissolution. This is
particularly true for weak acids and weak bases ex-
hibiting high pKa values. However, weak bases
with low pKa values may tend to precipitate in the
small intestine and in the stomach when the pH of
the GI contents is elevated due to food.
• Class III compounds are low permeability, high sol-
ubility. Therefore, issues associated with drug per-
meability can markedly affect drug absorption.
Many of these compounds also exhibit region-de-
pendent permeability. Accordingly, while food
will not affect drug dissolution, it can alter drug ab-
sorption (e.g., viscosity of meal inducing a physical
barrier to drug absorption). However, the mecha-
nism and corresponding magnitude of food effects
are variable across this class of compounds and
therefore difficult to predict.
MEMBRANE TRANSPORTERS
The intestinal absorption of a drug product is largely
governed by its dissolution characteristics, drug solu-
bility and permeability, and the stability of the drug on
exposure to the gut wall and its contents. However,
there are numerous instances when the amount of drug
reaching the hepatic portal circulation is inconsistent
with expectations based on these properties. Often-
times, unexpected bioavailability characteristics (ei-
ther greater or lower than expected) can be attributed to
the involvement of membrane transporter proteins.
This observation has led to a surge of studies focusing
on the identification and role of molecular transporters
in modifying drug pharmacokinetics in both human
and veterinary species.
Transport proteins have been implicated in both in-
flux and efflux processes across a host of tissues, in-
cluding the intestine, kidney, liver, and the central ner-
vous system.88-91 Moreover, genetic variations in trans-
porter gene sequences have been implicated in several
severe genetic disorders. For this reason, Yan and
Sadee92 have developed a Web-accessible interactive
human membrane transporter database that contains
information such as genetic sequence, gene family,
transporter structure, function and substrate, tissue
distribution of the transporter, and genetic disorders
associated with transporter sequence variants.
In general, membrane transporter activities tend to
fall within the following classifications:88
• Facilitative transporters: passive transporters that as-
sist in thepassageof a single solute (uniporter) downan
electrochemical gradient.
• Active transporters: transporters that move solutes
against an electrochemical gradient and therefore must
be coupled to the generation of free energy.
a. Ion pumps: active transporters coupled to an energy-
yielding chemical or a photochemical reaction. In
most cases, these ion pumps result in a net move-
ment of charges, generating a voltage difference
across the membrane.
b. Secondary active transporters: use the voltage and
ion gradients generated by the primary active
transporters.
i. Cotransporters (symporters): move two or more
different solutes in the same direction.
ii. Antiporters: move two or more different solutes
in opposite directions, exploiting a chemical gra-
dient for one of the solutes.
Table I contains examples of transporter families
and the substrates whose intestinal absorption is be-
lieved to be linked in some manner to carrier-mediated
transport.
The intestinal location of these transporters appears
to be site specific. For example, transporter-mediated
iron absorptionoccurs primarilywithin theupper duo-
denum while vitamin B12 absorption occurs in the ter-
minal ileum.95 Additional specificity is conferred by
apical to basal differences in transporter distribution.94
While the vast majority of transporters are located on
apical membrane surfaces, some exist primarily on
basolateral membrane surfaces. The latter include
the Na+/A amino acid transporter, Na+/ASC amino
acid transporter, GLUT2 hexose transporter, and Na+-
independent folic acid transporter. In addition, others
may be found on either membrane surface, including
y+ amino acid transporters, Na+/H+ antiporters, and an
inorganic phosphate transporter.
Some drugs act as a substrate for multiple trans-
porter systems, as is the case with several anionic
β-lactams.96 In these situations, absorption is compli-
PHARMACOKINETICS AND PHARMACODYNAMICS 633
UNDERSTANDING THE FACTORS AFFECTING DRUG ABSORPTION
cated by drug affinity for both influx and efflux mecha-
nisms. Therefore, any number of factors may be capa-
ble of influencing drug bioavailability.
Drug exsorption has been associated with a wide
range of substances and ahost of potential transporters.
Efflux systems have been implicated in the intestinal
membrane transport of organic anions (such as some
cephalosporins, β-lactams, and fluroquinolones),
glucuronide conjugates (presumably via apical mem-
brane MRP2 transporter molecules), prostaglandins,
and certain ester prodrugs.97-99 Intestinal secretion of
Phase II metabolites may also be subject to binding and
transport via the breast cancer resistance protein
(BRCP), an ATP-binding cassette “half-transporter” re-
sponsible for extruding compounds such as topetecan
across the luminal surface of the small intestine.99
Due to their broad range of substrate specificity,
much of the recent research has focused on P-gp and
the dipeptide transporter, PepT1. Accordingly, the re-
maining portion of this review will concentrate on
these two transporter systems.
PepT1
The acidic pH generated by the brush-border Na+/H+
exchanger serves as the driving force for intestinal ab-
sorption of dipeptides, tripeptides, and peptoid
drugs.88,93 However, while penetration of the apical
membrane appears to depend on an apical H+/dipeptide
transporter (PepT1), after entering the enterocyte, those
proteins that are resistant to hydrolysis by intracellular
peptidases are transported across the basolateral mem-
brane by an H+-independent transporter, possibly
PepT2.93 PepT1 is thought to exist on the apical mem-
branewhile the relatedPepT2 is thought to be localized
on the basolateral membrane surface.94
The density of PepT1 increases from the duodenum
to the ileum, being most abundant at the villus tip. Its
expression is regulatedbynutritional status, increasing
in the presence of starvation. It is also relatively unaf-
fected by a variety of drugs (such as 5-fluorouracil) that
can adversely affect the function of other transporter
systems. This observation has raised the suggestion
that drugswhose absorption is linked toPepT1may ex-
hibit less variability during a course of therapy than
would compounds whose absorption is associated
with a less robust transporter mechanism.90
PepT1 possess two putative sites for phos-
phorylation by protein kinase C, with protein kinase C
activation suppressing peptide transport activity in
Caco-2 cells.100 PepT1 is also negatively affected by an
increase in the level of cAMP, presumably a conse-
quence of a cAMP-induced stimulation of protein
kinase C.101
Certain PepT1 substrate structure-activity rela-
tionships have been identified. Accordingly, while
some exceptions do occur (e.g., several angiotensin-
converting enzyme inhibitors), most substrates exhibit
the following features:93,102,103
• a free C-terminal carboxyl group or a group capable of
hydrogen bond formation,
• an amino group or a weakly basic group at the
N-terminus,
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Table I Transporters and Their Substrates90,93,94
Transporter Substrates
Lipid transporters/bile acid transporters Fatty acids, cholesterol, (lipophilic drug?)
Monocarboxylate transporters (organic anionic Salicyclic acid, pravastatin, NSAIDs, some fluroquinolones
transporters)
Organic cation transporters Epinephrine, choline, dopamine, guanidine, antiarrhythmics, several
antihistaminics
Nucleoside transporter Nucleoside analogues used as antiviral and anticancer compounds
Intestinal dipeptide transporter β-lactam antibiotics, angiotensin-converting enzyme inhibitors,
thrombin inhibitors, thyrotropic-releasing hormone
Amino acid transporters Gabapentin, baclofen, L-alpha-methyl dopa, L-dopa
Vitamin transporters Valproic acid, salicylic acid, penicillins, methotrexate
Phosphate transporter Fosfomycin, phosphonoacetic acid, phosphopropionic acid
P-glycoprotein (P-gp) Etopside, vincristine, paclitaxel, ofloxacin, ciprofloxacin, cyclosporin,
peptides, some organic cations, vinblastine
• highest affinity is associated with molecules that exist
as zwitterions,
• a C-terminal amino acid in its L-configuration.
Compounds absorbedvia the activity of dipeptide trans-
porters exhibit saturable absorption. Consequently, sub-
strate intestinal permeability (Pw) can generally be de-
scribed by one of the two following equations:104
Pw = Jmax/(Km + Cw) + Pm
or
Pw = Pc/[1 + (Cw/Km)] + Pm,
where Jmax is the maximum transport rate, Cw is the in-
testinal wall concentration, Km is the molar concentra-
tion of substrate at 1/2 Jmax, Pc is the permeability de-
fined by the carrier-mediated transport, and Pm is the
intestinal permeability attributable to passive
diffusion.
The central nervous systemmayplay a role in stimu-
lating intestinal PepT1 activity.105 In this regard,
α2-adrenergic stimulation was found to enhance
Caco-2 cell substrate absorption by increasing the
translocation of the cytoplasmic transporter molecule
to the apicalmembrane. It didnot appear to act by alter-
ing transporter binding affinity.106 Although the exact
mechanism for this apparent increase in translocation
was not determined, it is believed to involve a cascade
of events modulated by the G-proteins. G-proteins are
responsible for regulating the trafficking of a number of
transporters.107,108 However, it is unclear if these events
could be translated to in vivo conditions since
α2-adrenergic receptors are abundant in crypt cells
(where PepT1 amounts are low) and are scarce in villus
cells (where PepT1 amounts are high).109-111 Neverthe-
less, Berlioz et al105,106 noted that based on the work of
Sundaram,112 the density of α2-adrenergic receptors in
the villi might be sufficient to stimulate PepT1.
While traditional efforts to increase drug bioavail-
ability have focused on drug solubility and permeabil-
ity, recent strategies have focused on the development
of prodrugs as a strategy for improvingdrug absorption.
By targeting broad-spectrum transporters such as
PepT1, drug absorption can be markedly enhanced.94
Once transported into the enterocyte, cytosolic en-
zymes convert the prodrug to its active form.90,94 Thus,
by developing formulations that use the inherent phys-
iological attributes of the enterocyte, the absorption of




Another family of proteins whose impact on drug ab-
sorption is currently under intense investigation is the
ATP-binding cassette (ABC) transporters. Based on
conserved sequences, there are estimated to be approx-
imately 48 ABC transporters of human cells. Mutations
of these genes have been associated with the develop-
ment of disease such as cystic fibrosis and obstetric
cholestasis. Overexpression of these transporters has
been implicated invarious formsofdrug resistance.113
A subfamily of ABC transporters is the multidrug re-
sistance proteins (MRP). The MRP-associated gene
family consists of seven members: MRP1, MRP2,
MRP3, MRP43, MRP5, MRP6, and MRP7.89,114 Numer-
ous names may be applied to the same protein. For ex-
ample, MRP1 = ABCC1 = MRP; MRP2 = ABCC2 =
cMOAT (canalicular multispecific organic anion trans-
porter); MRP3 = ABCC3 = MOAT-D = cMOAT-2; MRT4
= ABCC4 = MOAT-B; MRP5 = ABCC5 = MOAT-C =
pABC11; MRP6 = ABCC6 = MLP-1. These transporters
differ both in terms of substrate specificity and in pri-
mary location within the body.89
In the gut, the MRP1 gene product located at the api-
cal surface membrane, P-gp, serves as an effective bar-
rier to the intestinal absorption of numerous sub-
strates.115 It also acts as ahighly efficientmechanism for
transporting a variety of substances from the blood
back into the intestinal tract.116 P-gp is located on the
apical surfaces of many organs, including the bladder,
kidney, brain, liver, lungs, pancreas, stomach, spleen,
esophagus, and the large and small intestines.117,118 In
the intestine, the ratio of fluxes from the basolateral to
apical versus the apical to basolateral direction ranges
from 1.4 to 19.8, depending on location within the GI
tract.115
P-gp uses ATP-derived energy to fuel the active
efflux of its substrates. Although not the sole energy-
dependent secretory mechanism affecting drug
bioavailability,119 P-gp appears to have the most wide-
spread importance due to its high intestinal concentra-
tion, its locationwithin the intestine, and its broad sub-
strate specificity. P-gp is located on the villus tip of the
apical brush-border membrane, with minimal or no
levels found within the intestinal crypts.120 Its activity
tends to increase progressively from the stomach to the
colon in humans,121 a consideration when developing
sustained-release dosage forms.
ABC transporter proteins share a common molecu-
lar structure. This includes two large transmembrane
domains (formingapathway throughwhich the solutes
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move) and two nucleotide binding sites. The
transmembrane domain proteins are composed of mul-
tiple membrane-spanning segments (alpha helices),
housing the substrate binding sites. The nucleotide
binding sites are located at the cytoplasmic membrane
surface and are responsible for coupling ATP hydroly-
sis with substrate translocation. The nucleotide bind-
ing sites appear to be linked by a short bridge of
intracellular transmembrane domain loops, and it is
believed that this bridge is responsible for the transfer
of signals between the nucleotide binding site and the
membrane-spanning proteins.113
Transmembraneproteins forma chamber that serves
as anopening to the external aqueous environment and
through which lipophilic substrates are believed to be
extracted. This protein is also believed to form two
large side entrances between the membrane proteins
and the inner bilayer leaflet, and it is through these side
entrances that small hydrophilic molecules may gain
access to the P-gp molecule.113,122 A dramatic
conformational change in the transmembrane domain
protein is believed tooccur on thebindingofATP to the
nucleotidebinding site, and it is the energyof this bind-
ing rather than the hydrolysis itself that may provide
the initial energy for the substrate translocation. The
conformational change is thought to also result in re-
duced binding site affinity, binding site reorientation,
and a reduction in substrate affinity as the binding site
is exposed to the aqueous chamber contents. This re-
sults in substrate release at thebasalmembrane surface.
Subsequent hydrolysis and ADP/Pi release return the
transporter protein to its original configuration.113
P-gp has been described as having at least four bind-
ing sites that allosterically communicate in a negative
heterotropic manner. One site appears to act solely as a
regulatory site, binding modulator but not transporter
substances. At least three sites are associated with drug
transport, with one of these three acting as both a trans-
porter and a regulator. Each site is proposed to exist in
either a high- or low-affinity state, with the allosteric
interaction between sites altering the equilibrium be-
tween these states.123 There is also evidence that P-gp
substrate affinity may vary as a function of intestinal
site.124
Upon studying the structure-activity relationship of
P-gp substrates, several points were noted.125 First,
membrane partitioning is the rate-limiting step in the
binding of substrates. Accordingly, hydrophobic inter-
actions play a predominant role for membrane parti-
tioning. However, numerous hydrophilic molecules
are also actively transported, most probably reflect-
ing the multiple potential points of entry to this
transporter protein. Substrate affinity does not ap-
pear to be affected by molecular charge since there
are examples of neutral, positively charged, and neg-
atively charged molecules that are effectively carried
by this transporter.99
Second, a compound must possess the ability to un-
dergo hydrogen bonding with the transporter as a
mechanism for activating the ATPase. The number and
strength of these hydrogen bonds determine the disso-
ciation of the P-gp-substrate complex. The binding of
compounds with a high number of hydrogen bond ac-
ceptor patterns can lead to a lowering of the ATPase ac-
tivation. Accordingly, the rate of hydrolysis appears to
be indirectly proportional to the number and strength
of hydrogen bond acceptor patterns per compound. If
two substrates are simultaneously applied to the P-gp,
the compound with the higher potential to form hydro-
gen bonds with P-gp will act as an inhibitor for the
other.125
Barrier functions are markedly enhanced by the
co-location of metabolizing enzymes and multidrug re-
sistance proteins.117,126 Cytochrome P450 (CYP) 3A and
P-gp are often colocated on the apical surfaces of small
intestinal villi, exhibiting overlapping substrate speci-
ficity and shared inducers and inhibitors. Via their co-
ordinated activities, drugs that are CYP3A substrates
are continually cycled between the enterocyte and the
gut lumen, thereby maximizing the extent of drug ex-
posure to the catabolizing enzyme. Upon P-gp inhibi-
tion, the drug undergoes only a single exposure to the
enzyme, leading to a decrease in drug degradation and
higher oral bioavailability. Nevertheless, despite their
closely aligned relationship, there appears to be inde-
pendent genetic regulation of these proteins, as evi-
denced by the lack of correlation in the magnitude of
the phenotypic expression of CYP3A and P-gp across
individuals.127
Considering thepotential impact ofP-gpandCYP3A
activity on drug bioavailability, Benet et al117 observed
that the fraction of drug absorbed could be predicted by
the following equations:
Foral = Fa • Fg • Fh,
where
Foral = the oral bioavailability of a compound.
Fa = the fraction of the oral dose that gets
absorbed.
Fg = the fraction of a dose that passes through the
gut into the hepatic portal blood without
being metabolized. Fg can also be described
as 1-ERg (where ERg is the gut extraction ratio).
Fh = the fraction of a dose that is not metabolized
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on first pass through the liver. Fh can also be
described as 1-ERh (where ERh is the hepatic
extraction ratio).
and
ERg = kmg/(kmg • ka),
ERh = CLh/Qh,
where ka is the absorption rate constant for the drug en-
tering the blood from the intestine, kmg is the rate con-
stant for drug metabolism in the gut, CLh is the hepatic
blood clearance, and Qh is the hepatic blood flow.
Ultimately, Foral can be modified by concomitant
exposure to substances that act as inducers or inhibi-
tors of these metabolic processes. P-gp inhibitors and
inducers act by altering ka. The absence of a corre-
sponding change in tmax can be explained by the con-
comitant change in substrate elimination from the
systemic circulation.117
As evidenced by drugs that are metabolically inert
such as talinolol128 and fexofenadine,129 P-gp contrib-
utes to dose-dependent oral bioavailability such that
bioavailability can increase solely due to efflux pump
saturation. In addition, intestinal absorption of sub-
strates can be increased through substrate competition,
ATP depletion, or changes in membrane fluidity.130,131
Numerous inhibitors such as verapamil, quinidine,
and nifedipine have also shown to increase the
bioavailability of P-gp substrates such as etopside,
paclitaxel, andvinblastine.94 Conversely, P-gp inducers
suchas rifampin candecrease thebioavailability of cer-
tain compounds by increasing total gut activity of this
efflux protein.132
The importance of P-gp may be most clearly seen by
the impact of the genetic mutations. In mice, the
mdr1a–/– genotype results in “knockout” mice that ex-
hibit a total absence of gut P-gp activity. These mice
were used to examine the P-gp role in limiting the in-
testinal absorption of paclitaxel.133 Paclitaxel AUC val-
ues after oral administration in wild-type mice
(mdr1a+/+) versus knockout mice (mdr1a–/–) were
11% and 35%, respectively. Intestinal secretion fol-
lowing intravenous administration was practically
eliminated in knockout mice, even though 40% of the
dose underwent intestinal secretion in the wild-type
mice. Similar differences in wild-type versus knockout
mice bioavailability were observed for such compounds
as vinblastine, digoxin, indinavir, and talinolol.91 An ef-
fect corresponding to the mdr1a–/–genetic variant in
mice was observed in humans, where certain varia-
tions in the MDR1 gene have been shown to alter both
the gut expressionofP-gpand theoral bioavailability of
P-gp substrates.134
Permeability enhancers such as the bile salt sodium
deoxycholate,135 fatty acids such as sodium caprate,135
and surfactants131 suchaspolysorbate 80,136 Cremophor
EL,137 and vitamin E138 can alter P-gp activity. The
mechanism by which these substances interact with
P-gp appears, at least in part, to involve a change in
membrane fluidity.
Dudeja et al131 provided data suggesting that surfac-
tants such as Solutol HS-15, Tween 40, and Cremophor
EL decrease lipid fluidity of both intact cells and iso-
lated crude plasma membranes. Similarly, the ATPase
activity of the sarcoplasmic reticulum calcium trans-
porter, Ca2+-ATPase, is decreased in the presence of
lower membrane fluidity.139 Furthermore, multidrug-
resistant Chinese hamster ovary cells were shown to
exhibit lower membrane fluidity than did their
drug-sensitive counterpart.140
In contrast, membrane fluidity was found to in-
crease in the presence of ether, benzyl alcohol, Tween
20, TritonX-100, andverapmil, and this increase in flu-
idity was correlated with the inhibition of P-gp ATPase
activity in multidrug-resistant hamster ovary cells.141
Moreover, the bile salt, taurochenodeoxycholate, and
verapamil increased membrane fluidity and decreased
P-gp activity in multidrug-resistant hamster ovary
cells.142
Although the reasons for these discrepancies are not
obvious, each of these studies consistently noted that
surfactants could alter drug efflux. The combination of
efflux transporter inhibition, enhancement of
transcellular diffusion, and facilitation of paracellular
diffusion results in substantially increased oral drug
bioavailability. Consequently, formulators are examin-
ing the use of these and other P-gp inhibitors as a for-




Organic Anions and Cations
An amphiphilic solute facilitator family with the capa-
bility of transporting organic anions and cations has
been recently defined.143 Although their full scope of
intestinal significance has yet to be determined, mem-
bers of this family are diverse, exhibiting a number of
characteristics, including the following:143
• a sodium-independent thiamin transporter;
• a sodium-independent and potential-dependent trans-
porter that mediates absorption of tyramine,
tryptamine, and disopyramide;
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• a sodium and potential-independent transporter that
mediates the absorption of choline and may be in-
volved in the secretion of organic ions through an or-
ganic cationic exchange mechanism;
• a proton/cation antiporter;
• aP-gp thatmediates secretionofhydrophobic cations;
• a polyamine transporter.
Lipid and Cholesterol
Transporters
Also of interest is the absorption of lipophilic com-
pounds such as long chain fatty acids (LCFA) and cho-
lesterol. Certainly, one of the pivotal steps in the ab-
sorptionofnonpolar lipids is itsmicellar solubilization
in the unstirred water layer of the intestine, generally
bybile salts.144 Uponcontacting thebrush-bordermem-
brane, the high lipophilicity of these compounds
should allow for absorption to occur simply by passive
diffusion. However, recent evidence suggests that al-
though cholesterol and LCFAs are expected to freely
diffuse through the enterocyte membrane, these com-
pounds exhibit saturable absorption. Putative trans-
porter proteins are concentrated in the stomach and on
the villus tips of the distal small intestine of rats.144,145
This is consistent with earlier findings that substances
such as linoleate appear to be absorbed via a carrier-
mediated process at low concentrations and by passive
diffusion after carrier saturation has occurred.146 More-
over, there may be several binding proteins influencing
the transport of lipophilic compounds.147
Intestinal cholesterol absorption is a complex pro-
cess, involving numerous enzymes and transporter
systems.148 Thurnhofer and Hauser149 successfully
identified a cholesterol-binding transport protein in
the small intestinal brush-border membrane that helps
transport cholesterol into the enterocyte. Moreover, ab-
sorption is dependent on the maintenance of the con-
centration gradient within the enterocyte. In this re-
gard, acyl CoA:cholesterol aceytltransferase (ACAT)
appears to be responsible for cholesterol ester synthe-
sis, the latter of which may be accountable for main-
taining an intracellular diffusion gradient for free di-
etary cholesterol in the presence of a high-cholesterol
diet.146,150
In addition to carrier-mediate processes, cholesterol
absorption also appears to be affected by the action of
multidrug-resistant effluxproteins, the latter appearing
to be the same transporter responsible for prohibiting
the absorption of plant sterol.146 It was noted that hu-
man mutations in ABC transporter genes are responsi-
ble for the development of sitosterolemia. Two of these
genes are expressed at highest levels in the gut and in-
testine and appear to result in sterol accumulation and
the development of atherosclerosis.151 Moreover, ani-
mal model studies reveal the impact of genetic
mutations on the presence of abnormal cholesterol and
bile salt metabolism.148 Therefore, given the growing
recognition of the importance of transporters in main-
taining cholesterol homeostasis, it is evident that these
transporters are becoming a target for new drug
therapies.
CLOSING STATEMENT
Drug absorption is a complex process that reflects the
potential interaction of a host of variables, both
physicochemical and physiologic. The skilled formu-
lation chemist artfully manipulates product properties
by the use of manufacturing methods and product ex-
cipients to increase the solubility and permeability of
problematic compounds. However, physiological vari-
ables, both endogenous (such as age, disease state, phe-
notype, and gender) and exogenous (such as food con-
sumption, nutritional status, concomitant medication,
and environmental exposure to other xenobiotics), can
markedly affect the absorption characteristics of a com-
pound.Byunderstanding thephysicochemical proper-
ties of a compound (such as its pKa, log P value, molec-
ular flexibility, hydrogen bonding dynamics, and
molecularweight) andby recognizing its affinity for the
various enzymes systems and transportermechanisms,
we can predict with some degree of accuracy a prod-
uct’s expected bioavailability. Thus, through an
awareness of a drug’s BCS characteristics and the
physiological processes affecting drug absorption, the
pharmaceutical scientist can better predict drug ab-
sorption and develop formulations that can maximize
product availability. Finally, this informationcanbe in-
valuablewhenconsidering thedrug’s prescribability in
the face of varying patient physiological status, pheno-
type, age, gender, or lifestyle.
With regard to membrane transporters, these mecha-
nisms and the factors that can alter their activity have
been the recent focus of much research activity. Ac-
cordingly, there appears to be a rapid rise in thenumber
of transporter molecules being identified across all or-
gans systems. These carrier-mediated transport pro-
teins are now being targeted as mechanisms for im-
proving oral drug bioavailability, such as the synthesis
of prodrugs to improve binding site affinity, concomi-
tant administration of substances that enhance the ac-
tivity of carrier-mediated influx systems, or by includ-
ing substances that act as inhibitors of efflux
transporters. By identifying the intestinal location of
specific transporter molecules, directed drug delivery
can be used to improve drug bioavailability. Moreover,
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an understanding of the genetic polymorphism of
drug transporters is hoped to enable scientists to better
design drugs that are targeted for improved
bioavailability within select patient populations and to
understand the causes for various malabsorption syn-
dromes. It is hoped that by understanding some of the
genetic mutations seen in the patient population, sci-
entists can better accommodate phenotypic variability
observed across clinical practices and treat conditions
resulting from defective transport systems.
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